NASDAQ:VERA

Vera Therapeutics Stock Predictions

Healthcare > Biotechnology

Buy VERA

*Your capital is at risk

$38.20

-0.230 (-0.598%)

At Close: Jun 23, 2026

Currently predicting for Wed, 24 Jun 2026

VERA Live board

Community Bull/Bear

Target Next close

Join the VERA prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

VERA Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For VERA

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

VERA Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	USD target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT VERA THERAPEUTICS, INC.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of ...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
IDYA $28.98	18.12%	Jun 12
DHI $146.71	6.29%	Jun 10
PHM $118.49	6.02%	Jun 10
EAT $140.46	17.09%	Jun 05
E ETD $20.67	3.19%	Jun 05

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by